Alvotech and Cipla Gulf FZ LLC (“Cipla Gulf”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), today announced that Alvotech and Cipla Gulf have entered into an exclusive partnership for the

Alvotech AVT02 is developed as a high concentration (100mg/mL) formulation, expected to be more convenient for patients, differentiating from most biosimilar competitors 407 participants enrolled in the Phase III study, at approximately 30 sites across Europe Simultaneous Phase I PK comparability

Alvotech and Abdi Ibrahim enter into an exclusive partnership for the development and commercialization of biosimilars in Turkey. Alvotech gains access to the fast-growing Turkish biosimilar market Abdi Ibrahim is Turkey’s leading pharmaceutical company having built the largest biotechnological

Alvotech today announced the appointment of Mark Levick as Chief Executive Officer, effective 5 August 2019. Mark brings over 18 years of global industry experience, with a very impressive track record of value creation and success in bringing new biosimilars to market.

Alvotech announced today that Abu Dhabi-based investment company, Yas Holding, has acquired a 2.5% stake in their business and signed an agreement for the exclusive partnership and supply of three Alvotech biosimilar candidates, which Yas Holding’s will commercialize in the MENA region.

Alvotech and Fuji pharma have entered into a binding agreement for the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar (Stelara®) in Japan.  Alvotech and Fuji Pharma recently announced Fuji´s ~US$50 million investment into Alvotech that further strengthens the

Alvotech enrolls first patient in clinical phase III study involving biosimilar version of HUMIRA® Alvotech’s AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors 400

Following the late 2018 announcement that Alvotech was to enter into a joint venture with Changchun High & New Technology Industries Group Inc (“CCHN”), representatives from the two companies met up last week to discuss the groundbreaking of the new facility.

Fuels growth and biosimilar development in a fast-growing market Alvotech announced today that it has successfully raised US$300 million through a private bond offering. Net proceeds from the capital raised will be used to fuel continued growth, refinance of existing debt and the further

Biopharmaceutical company Alvotech announced today that Japan-based Fuji Pharma has acquired a 4.2% stake in the business for approximately US$50 million. Alvotech and Fuji Pharma recently announced an exclusive agreement for development and commercialization of biosimilars in Japan.